Bateman, Andrew - University of Southampton

个人简介

Dr Andrew Bateman was appointed Senior Lecturer, Cancer Sciences, University of Southampton in 2002 and was recipient of a Cancer Research UK Clinician Scientist award. He had graduated from St Bartholomew’s Hospital Medical School in 1989 and undertaken general medical training in London and the South East. He was appointed to a Clinical Oncology Registrar Training post at the Hammersmith Hospital in 1993, spent a year (’95-’96) in Christchurch, New Zealand, completing the FRCR in ’97. He then entered research as an ICRF clinical research fellow in the laboratory of Dr Richard Vile, initially at the Hammersmith and then subsequently in the Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota. In 2001-2 Dr Bateman completed his Clinical Oncology training at Mount Vernon Hospital, before obtaining a CR UK Clinician Scientist Fellowship and moving to Southampton. Here he has developed a clinical practice in gastrointestinal malignancy, a focus in clinical trials, and research in cancer immunology and immunotherapy.

研究领域

Dr Andrew Bateman’s research is focused on understanding the tumour micro-environment, assessing potential predictive markers of response to conventional cancer treatments, as well as introducing novel therapies in to the clinic. These projects are conducted with relevance to gastro-intestinal cancers. Oesophageal cancer Adenocarcinoma of the oesophagus and oesophago-gastric junction has become the predominant histological tumour type seen in the UK. The majority of cases are thought to evolve through a process of metaplasia (Barrett’s), dysplasia and on to cancer. In conjunction with surgical and pathology colleagues we have built up a database of over 200 patients with matched clinical and pathology covering this spectrum of change in the lower oesophagus. This database is currently being interrogated. The work aims to identify potential drivers of malignant development, neo-antigen expression, predictors of response to neo-adjuvant therapy as well as assessment of the tumour micro-environment with particular focus on the immune environment. A longterm aim will be to design rational immunotherapy strategies for adjuvant treatment of oesophago-gastric cancer. Immunotherapy trials In collaboration with Professor Ottensmeier, Dr Bateman has recently obtained Cancer Research UK funding to conduct a Phase 2 DNA vaccine trial in advanced colorectal cancer: The Acacia Trial. This will be a randomized, multi-centre trial which will address the effectiveness of vaccination in this group, the interaction between vaccine and chemotherapy, and the advantage of a dual antigen vaccine strategy. Clinical Research Dr Bateman is Clinical Lead of the Central South Coast Cancer Research Network (CSCCRN). The CSCCRN recruits large numbers of patients in to NIHR Trials across a broad range of cancer specific sub groups. Dr Bateman is also active in the radiation subgroup of the Upper GI site specific group and is involved in developing a Phase 2 study of neo-adjuvant chemoradiotherapy in oesophageal cancer.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma - Noble, Fergus, Mellows, Toby, McCormick Matthews, Leo H., Bateman, Adrian, Harris, Scott, Underwood, Tim, Byrne, James P., Bailey, Ian S., Sharland, Donna M., Kelly, Jamie J., Primrose, John N., Sahota, Surinder S., Bateman, Andrew R., Thomas, Gareth J and Ottensmeier, Christian H. Published:2016Publication:Cancer Immunology ImmunotherapyVolume:65, (6)Page Range:651-662doi:10.1007/s00262-016-1826-5PMID:27020682 Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunological and clinical outcomes - Mccann, Katy J., Mander, Ann, Cazaly, Angelica, Chudley, Lindsey, Stasakova, Jana, Thirdborough, Stephen M., King, Andrew, Lloyd-Evans, Paul, Buxton, Emily, Edwards, Ceri, Halford, Sarah, Bateman, Andrew, O'Callaghan, Ann, Clive, Sally, Anthoney, Alan, Jodrell, Duncan I., Weinschenk, Toni, Simon, Petra, Sahin, Ugur, Thomas, Gareth J., Stevenson, Freda K. and Ottensmeier, Christian H. Published:2016Publication:Clinical Cancer ResearchPage Range:1-33doi:10.1158/1078-0432.CCR-15-2507 PMID:27091407 Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus - Noble, Fergus, Nolan, Luke, Bateman, Adrian C., Byrne, James, Kelly, Jamie, Bailey, Ian, Sharland, Donna, Rees, Charlotte, Iveson, T., Underwood, T.J. and Bateman, Andrew R. Published:2013Publication:World Journal of GastroenterologyVolume:19, (48)Page Range:9282-9293doi:10.3748/wjg.v19.i48.9282 Altered expression of two-pore domain potassium (K2P) channels in cancer - Williams, Sarah, Bateman, Andrew and O'Kelly, Ita Published:2013Publication:PLoS ONEVolume:8, (10)Page Range:1-11doi:10.1371/journal.pone.0074589